I am excited to share the first public reveal of BeiGene’s tremendous progress made on iPSC-derived γδ T cells at ASH 2024.
Though our very first experiment was initiated only 2.5 years ago amidst ongoing laboratory construction and pandemic, fast forward to this day, we have already 1) generated a proprietary, well-characterized GMP grade iPSC clone collection designated for our future γδ T and αβ T cellular products, 2) established our unique efficient, enrichment-free, feeder-free methodologies that deliver impressively high purity and high expansion fold for our iPSC derived γδ T and iPSC derived CD8 αβ T platforms, and 3) engineered proprietary genetic elements that further enhance the longevity and potential efficacy of our effector cell populations. Our platforms are designed to allow plug-and-play for a variety of CAR-T and TCR-T cell therapies with potential to address unmet needs in diverse indications.
The ongoing efforts of a talented and committed cell therapy research team, along with incredible empowerment and support from the BeiGene’s executive team, have enabled these exciting technology achievements within a short period of time.
I truly believe that the success of #iPSC-derived cell therapies will not only dramatically reduce the cost-of-goods but also enhance the accessibility of cell therapies, hence democratizing the application of these transformative medicines globally.
The team and I are looking forward to sharing more at ASH and contributing to advancing research in this important field through conversations with experts, industry peers, and future partners. Please feel free to reach out to me on LinkedIn to learn more.
Onward and upward!
See our ASH abstract here: https://bit.ly/3UDBK97
#ASH2024 #CellTherapy #iPSC-Derived
